Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
  1. 4 Grant or award Director acquired 11,875 shares (grant or award)
  2. 4 Grant or award Director acquired 3,750 shares (grant or award)
  3. 4 Open-market sale 10% owner sold 200,000 shares at $1.09 ($218,000)
  4. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $1.07 ($10,665)
  5. 4 Open-market sale 10% owner sold 2,532,000 shares at an average $1.13 ($2,872,477)
  6. 4 Open-market buy Director bought 8,610 shares at $1.18 ($10,133)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Grant or award Director acquired 10,523 shares (grant or award)
  16. 4 Grant or award Director acquired 9,705 shares (grant or award)
  17. 4 Grant or award Director acquired 3,065 shares (grant or award)
  18. 4 Grant or award Director acquired 9,705 shares (grant or award)
  19. 4 Grant or award Chief Development Officer acquired 50,250 shares (grant or award)
  20. 4 Grant or award Chief Financial Officer acquired 46,500 shares (grant or award)

Page 4 of 11 · 216 filings